Monte Rosa Therapeutics (NASDAQ: GLUE) insider files Form 144/A stock sale

Rhea-AI Filing Summary

Monte Rosa Therapeutics filed an amended Form 144 notice covering a planned stock sale. The filing indicates a proposed sale of 5,466 shares of common stock through broker Rockefeller Capital Management on the NASDAQ, with an approximate sale date of January 7, 2026.

The securities to be sold stem from a restricted stock unit (RSU) stock award for 21,865 units, acquired on January 2, 2025 from the issuer as compensation, with the payment date listed as January 2, 2026.

The document also reports that seller Markus Warmuth sold 10,135 Monte Rosa Therapeutics shares on January 5, 2026, generating gross proceeds of $153,759.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Capital Management 500 Boylston Street Suite 1300 Boston MA 02116	5466	128372.00	65117761	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
RSU	01/02/2025	Stock Award	From Issuer			21865	01/02/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Markus Warmuth 300 Pier 4 Blvd Unit 3C Boston MA 02210	Monte Rosa Therapeutics	01/05/2026	10135	153759.00

144/A: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Monte Rosa Therapeutics' (GLUE) latest Form 144/A filing disclose?

It discloses an amended notice for the planned sale of 5,466 shares of Monte Rosa Therapeutics common stock through Rockefeller Capital Management on the NASDAQ, with an approximate sale date of January 7, 2026.

How many Monte Rosa Therapeutics (GLUE) shares are planned to be sold under this Form 144/A?

The filing lists a proposed sale of 5,466 shares of Monte Rosa Therapeutics common stock, with an aggregate market value of $128,372.00 as shown in the securities information table.

How were the Monte Rosa Therapeutics (GLUE) shares in this Form 144/A acquired?

The filing shows the securities were acquired as RSUs via a stock award from the issuer on January 2, 2025, covering 21,865 units, identified as compensation with a payment date of January 2, 2026.

What recent Monte Rosa Therapeutics (GLUE) share sales are reported in the past 3 months?

The document reports that Markus Warmuth sold 10,135 Monte Rosa Therapeutics shares on January 5, 2026, generating gross proceeds of $153,759.00.

Which broker and exchange are involved in the planned Monte Rosa Therapeutics (GLUE) share sale?

The planned sale of 5,466 shares is listed through broker Rockefeller Capital Management, with trading on the NASDAQ securities exchange.

What type of securities are covered in this Monte Rosa Therapeutics (GLUE) Form 144/A?

The filing covers common stock of Monte Rosa Therapeutics and notes RSUs acquired as a stock award that form the basis of the planned sale.